CanCuRX
Pancreatic Cancer Treatment
StartupCanCuRX is a Haifa-based startup in the Health Tech & Life Sciences sector, established in 2016. Pancreatic Cancer Treatment. CanCuRX was founded by Fuad Fares, Prof. and Lital Sharvit, PhD. Key investors include Carmel Innovation Fund. The company has 1-10 employees. Core technologies: Biologicals, Herbals.
The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQHaifa
- DistrictNorth District
- Last RoundUndisclosed
- Carmel Innovation Fund
Fuad Fares, Prof.Founder
Lital Sharvit, PhDCo-founder
1 article covered by sources including www.jpost.com.
What does CanCuRX do?
CanCuRX is a preclinical-stage biopharmaceutical company aiming to improve survival for patients with pancreatic cancer through the development of a novel treatment based on the properties of a mushroom-derived compound that arrests pancreatic cell growth. CanCuRX is working with the Carmel Innovations Fund of the University of Haifa. CanCuRX has patents registered for the mushroom strain, the extract prepared from it, and the treatment process.
Who founded CanCuRX?
CanCuRX was founded in 2016 by Fuad Fares, Prof. (Founder), Lital Sharvit, PhD (Co-founder).
What sector is CanCuRX in?
CanCuRX operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, Biomaterials & Tissue Engineering, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients, Life Sciences, Pharmaceuticals.
Where is CanCuRX located?
CanCuRX is based in Eshkol Tower, University of Haifa, 3498838 Israel, North District.